WS
CNCR

Wedbush Securities’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Wedbush Securities’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,661
Closed -$202K – 1184
2021
Q3 		$202K Sell
6,661
-556
-8% -$16.8K 0.01% 1067
2021
Q2 		$230K Sell
7,217
-822
-10% -$24.8K 0.01% 994
2021
Q1 		$241K Buy
8,039
+1,616
+25% +$52.6K 0.01% 910
2020
Q4 		$204K Buy
+6,423
New +$193K 0.02% 780

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return

Wedbush Securities's CNCR Position: Q4 2021 in Review

Wedbush Securities sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q4 2021, closing a stake of 6,661 shares — an estimated $202K sold.

Wedbush Securities first reported a position in CNCR in Q4 2020 and held it in 4 quarters. The position peaked at $241K in Q1 2021. 25 funds tracked by Wall St. Rank hold CNCR as of Q4 2021.

  • Wedbush Securities reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q4 2021 after selling out during the quarter.
  • Wedbush Securities sold 6,661 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q4 2021, an estimated $202K.
  • Wedbush Securities first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q4 2020 and held it in 4 quarters.
  • Wedbush Securities's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $241K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q4 2021.

Based on Wedbush Securities's 13F filing for Q4 2021, filed 13 Jan 2022.